Trulicity(Dulaglutide)
LLY
Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Eli Lilly and Company
$5.45B
Medicare cost, 2024
$5.45B
Medicare cost, 2024
Medicare drug plans spent $5.5 billion on Trulicity (dulaglutide) in 2024, for 4.3 million prescriptions and refills filled by 788,414 patients. It ranks 6th among all drugs by Medicare drug plan spending. Spending fell 26% from 2023 to 2024. California accounts for the most spending ($402.6 million, 7% of the total).
Medicare cost, 2024
$5.45B
-25.9% from 2023
Prescriptions
4.3M
$1,266.91 per claim
Patients
788K
216,578 prescribers
Total spending, 2024
$5.45B
$6,915.21 per patient
Questions and answers
How much does Medicare spend on Trulicity?
Medicare prescription drug plans paid $5.45B for Trulicity in 2024, for 4,303,409 prescriptions and refills to 788,414 patients (down 25.9% from 2023). The average cost per claim was $1,266.91.
Which state spends the most on Trulicity?
California had the highest Medicare cost for Trulicity in 2024: $402.6M for 323,595 claims, followed by New York ($397.6M).
Who prescribes Trulicity the most?
Carlos R Figueroa Nunez, endocrinology in San Juan, PR, had the highest Medicare cost for Trulicity in 2024: 3,098 claims costing $3.2M.
Who makes Trulicity?
Trulicity is made by Eli Lilly and Company (LLY), listed in the Medicare spending data as Eli Lilly & Co..
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Trulicity was $5.45B in 2024, after a high of $7.36B in 2023.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Trulicity, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Carlos R Figueroa Nunez San Juan, PR | Endocrinology | 3,098 | 394 | $3.2M |
| Stella Ilyayeva Rego Park, NY | Internal Medicine | 1,736 | 340 | $2.0M |
| Eugenio Angueira-Serrano Miami, FL | Endocrinology | 1,812 | 365 | $1.9M |
| Carlos A Pla Fernandez Tampa, FL | Endocrinology | 1,578 | 207 | $1.6M |
| Jane Mayrin Philadelphia, PA | Endocrinology | 1,481 | 173 | $1.5M |
| Iraklii Buziashvili Brooklyn, NY | Endocrinology | 1,227 | 257 | $1.3M |
| Jamal Hammoud Flint, MI | Endocrinology | 886 | 231 | $1.3M |
| Jose M Garcia Mateo Ponce, PR | Endocrinology | 1,160 | 153 | $1.2M |
| Farhad Farjoudi San Diego, CA | Endocrinology | 736 | 172 | $1.2M |
| Robert J Pearlstein Plymouth Meeting, PA | Internal Medicine | 1,561 | 186 | $1.1M |
| Jean C Pujals Kury Bayamon, PR | Internal Medicine | 1,102 | 152 | $1.1M |
| Nduche C Onyeaso Fayetteville, NC | Endocrinology | 745 | 173 | $1.1M |
| Phong H Bui Fountain Valley, CA | Internal Medicine | 808 | 131 | $1.1M |
| Joymon K Sebastian Dartmouth, MA | Nurse Practitioner | 889 | 161 | $1.1M |
| Natasha Rodriguez Chicopee, MA | Physician Assistant | 1,003 | 182 | $1.1M |
| Miguel A Ariza Dracut, MA | Internal Medicine | 804 | 148 | $1.1M |
| Hemant T Thawani Grand Blanc, MI | Endocrinology | 547 | 130 | $988K |
| Mushtaq A Syed Indiana, PA | Internal Medicine | 876 | 185 | $972K |
| Ayman Elkadry Huntington, WV | Endocrinology | 904 | 188 | $965K |
| Monica G Robles Anniston, AL | Endocrinology | 652 | 158 | $953K |
| Anant Jeet Lorain, OH | Endocrinology | 754 | 144 | $952K |
| Joselito C Cabaccan San Jose, CA | Endocrinology | 654 | 148 | $949K |
| Jessica I Rosa Carolina, PR | Endocrinology | 781 | 116 | $907K |
| Natallia Kleshchanka Staten Island, NY | Nurse Practitioner | 843 | 191 | $903K |
| Ashutosh S Pareek Salem, MA | Endocrinology | 511 | 125 | $889K |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 199,514 | 4,609,369 | 839,891 | $6.22B |
| 2023 | 219,878 | 5,313,751 | 938,286 | $7.36B |
| 2024 | 216,578 | 4,303,409 | 788,414 | $5.45B |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Eli Lilly & Co. | 4,305,141 | $5.45B |
Medicaid spending by quarter
Amount reimbursed by state Medicaid programs, all states
Amount reimbursed
Codes
- National drug codes (packages)
- 11
- RxNorm concept IDs
- 1551295, 1551300, 1551304, 1551306, 2395777
- Application numbers
- BLA125469
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 89,369 side-effect reports named dulaglutide, the active ingredient of Trulicity (reports from 2011 on). 23,531 of them (26.3%) were serious, 1,706 named a death and 11,056 named a hospital stay. The reactions named most often were nausea, injection site pain and blood glucose increased. 37,504 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
89,369
5,875 in 2025 (-19.4% from 2024)
Serious
26.3%
23,531 reports
Deaths named
1,706
1.9% of reports
Hospital stays
11,056
12.4% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Trulicity?
89,369 reports from 2011 through September 2026 named dulaglutide, the active ingredient of Trulicity. 23,531 of them (26.3%) were serious, 1,706 named a death and 11,056 named a hospital stay.
What are the most reported side effects of Trulicity?
10,580 reports named nausea, the reaction named most often, followed by injection site pain (10,019) and blood glucose increased (9,960). In the last 5 years the reaction named most often was injection site pain (4,301 reports). A report can name several reactions.
How many side-effect reports named Trulicity in 2025?
5,875 reports were received in 2025 (-19.4% from 2024). 2026 so far: 3,673 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Trulicity caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Trulicity caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Makers on the stock market:
LLY·LLY drug pipeline - Drug approvals (1 approval on file for dulaglutide) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (dulaglutide) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.